Lisata Therapeutics bolsters its board and Audit Committee with the appointment of a seasoned biopharma CFO, aiming to leverage extensive public-company financial leadership.
Appointment of a veteran biopharma CFO to the board adds financial expertise but has no immediate operational or financial impact.
Lisata Therapeutics has appointed a veteran biopharma CFO with over 15 years of public-company experience to its board. The new director will also serve on the company's Audit Committee, bringing expertise in financial leadership across drug development and commercial launch phases.
The new board member, a veteran biopharma CFO, will provide financial leadership and serve on the company's Audit Committee.